TAO Synergies Inc.

Explanatory Note From August 23, 2013 to December 6, 2020, Synaptogenix, Inc. (formerly known as Neurotrope Bioscience, Inc.) (the Company or Synaptogenix ) was a wholly owned subsidiary of Neurotrope, Inc. ( Neurotrope ). Neurotrope’s operations were solely those of Synaptogenix. On May 17, 2020, Neurotrope announced plans for the complete legal and structural separation of Synaptogenix from Neurotrope (the Spin-Off ). Under the Separation and Distribution Agreement between Neurotrope and Synaptogenix (the Separation and Distribution Agreement ), Neurotrope distributed all of its equity interest in Synaptogenix to Neurotrope’s stockholders. Following the Spin-Off, Neurotrope does not own any equity interest in Synaptogenix, and Synaptogenix operates independently from Neurotrope. On December 6, 2020, Neurotrope approved the final distribution ratio and holders of record of Neurotrope common stock, Neurotrope preferred stock and certain warrants as of November 30, 2020 received a pro rata distribution of all the equity interest in Synaptogenix. On June 25, 2025, we filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation with the Secretary of State for the State of Delaware, effective June 26, 2025, to change the name of the Company from Synaptogenix, Inc. to TAO Synergies Inc. Additionally, the ticker symbol for the Company’s common stock on The Nasdaq Capital Market was changed from SNPX to TAOX. On September 26, 2025, we formed a subsidiary TAOX Florida Inc.